Modulation of Cerebral Blood Flow Using Iron Chelators

Hypoxia-Inducible Transcription Factor 1 (HIF-1)in Vascular Aging

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01365104

Acronym

DFO

Enrollment

Registered

2011-06-03

Start date

2008-03-31

Completion date

2014-12-31

Last updated

2015-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Problem of Aging, Stroke

Keywords

brain blood flow, stroke, cerebrovascular, aging, cerebrovascular hemodynamics

Brief summary

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Interventions

DRUGdesferrioxamine

intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy adults between the ages of 18-80 years.

Exclusion criteria

* subjects taking vasoactive medications, * hypertension, * pregnant women, smokers, * COPD, * asthma, * diabetes mellitus, * intracranial or carotid stenosis, * hepatic disease, * renal disease, * bone marrow suppression, * cardiac disease, * heart failure, * iron deficiency, * history of cancer, * history of head trauma, * subarachnoid hemorrhage, * central nervous system vasculitis, * multiple sclerosis, * migraines, * seizures, * sickle cell disease or trait, * cardiac arrhythmia, * unable to give informed consent, or * poor transcranial Doppler insonation windows.

Design outcomes

Primary

Measure	Time frame	Description
Define change from baseline cerebral blood flow after receiving DFO infusion.	baseline, 3hr, 6hr, 9hr	Cerebral blood flow is measured with transcranial Doppler ultrasound at baseline and then study drug is initiated. Blood flow is measured again after 3 hours of infusion, 6 hours of infusion, then once more 3 hours after the infusion is complete.
Determine if DFO changes blood HIF-1 levels from baseline and whether this correlates with changes in cerebrovascular hemodynamics.	baseline, 3hr, 6hr, 9hr	Blood samples are taken at each time point and will be correlated with ultrasound blood flow measures taken at baseline, 3hrs of infusion, 6hrs of infusion, and 3 hours after infusion is complete.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026